Covalent Inhibitor Discovery in Chemical Biology

Covalent inhibitors represent a class of small molecules that form irreversible or quasi‐irreversible bonds with their protein targets, offering enhanced potency, prolonged duration of action and the potential for exquisite selectivity. The resurgence of interest in covalent strategies has been driven by advances in chemical biology, high‐throughput screening and structural analysis. Modern approaches employ electrophilic “warheads” tuned to react selectively with nucleophilic amino acids, most commonly cysteine but extending to lysine, tyrosine and other residues. Strategies span from targeted design—guided by protein x-ray structures or computational covalent docking—to unbiased fragment screening and proteome‐wide chemoproteomic profiling. Together, these methods enable the discovery of covalent ligands for challenging targets, the mapping of reactive hotspots across the proteome and the development of chemical probes and therapeutic candidates with improved efficacy and safety profiles. Applications range from fundamental studies of enzyme mechanism and signalling pathways to the development of next‐generation kinase inhibitors, protease modulators and epigenetic regulators.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Covalent Inhibitor Discovery in Chemical Biology publication trend

The graph below shows the total number of articles in covalent inhibitor discovery in chemical biology across all publications each year (not limited to Nature Index journals).

Technical terms

Covalent inhibitor: A small molecule that forms a stable, typically irreversible, bond with a target protein residue, enhancing potency and duration of action.

Warhead: An electrophilic functional group within a covalent inhibitor designed to react selectively with a nucleophilic amino acid side chain.

Fragment-based drug discovery: A method that screens low-molecular-weight chemical fragments for weak but efficient binding, which are then elaborated into higher-affinity ligands.

Chemoproteomics: An approach combining chemical probes and mass spectrometry to profile protein–ligand interactions and reactive sites across the proteome.

Latent electrophile: A functional group that is relatively inert in solution but becomes activated for covalent bond formation within the microenvironment of a protein binding site.

References

1. Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening. Journal of the American Chemical Society (2019).
2. Progress with covalent small-molecule kinase inhibitors. Drug Discovery Today (2018).
3. Analysis and Functional Prediction of Reactive Cysteine Residues*. Journal of Biological Chemistry (2011).
4. Theory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls. Molecules (2015).
5. Characterising covalent warhead reactivity. Bioorganic & Medicinal Chemistry (2019).
6. Fragment-based covalent ligand discovery. RSC Chemical Biology (2021).
7. The Alkyne Moiety as a Latent Electrophile in Irreversible Covalent Small Molecule Inhibitors of Cathepsin K. Journal of the American Chemical Society (2019).